Skip to main content
main-content

Insulin degludec

06-15-2022 | Insulin | News

Liver-targeted insulin reduces hypoglycemic events

Switching 1% of standard bolus insulin lispro to a liver-targeted formulation decreases hypoglycemic events without affecting glucose control, OPTI-1 study findings indicate.

11-09-2021 | Travel | News

Insulin degludec could simplify travel across times zones

Insulin degludec offers similar glycemic outcomes to insulin glargine U100, along with more straightforward dosing, for people with insulin-treated diabetes crossing time zones, a small study suggests.

10-04-2021 | EASD 2021 | Conference coverage | News

Real-world data show comparable benefits for second-generation insulins in type 2 diabetes

Insulin-naïve people with type 2 diabetes initiating the second-generation basal insulins glargine 300 or degludec 100 experience similar improvements in glycated hemoglobin levels, show data from the real-world RESTORE-2 study.

06-27-2021 | ADA 2021 | Conference coverage | News

Further support for insulin degludec to reduce nocturnal hypoglycemia risk in type 1 diabetes

Use of insulin degludec is associated with a reduced risk for recurrent nocturnal hypoglycemia as measured by hourly plasma glucose among adults with type 1 diabetes, suggest findings from the overnight substudy of the HypoDeg trial.

06-26-2021 | ADA 2021 | Conference coverage | News

SURPASS-3: Tirzepatide proves better option than degludec for type 2 diabetes

The SURPASS-3 findings show that people with type 2 diabetes can obtain better glycemic control with tirzepatide than insulin degludec, while losing rather than gaining weight.

03-31-2021 | Older adults | News

Glargine-300 might be preferable for older people with type 2 diabetes

Analysis of older participants in the BRIGHT trial suggests that this subgroup may do slightly better with insulin glargine-300 than with degludec.

Mature man injecting insulin in his abdomen

03-24-2021 | Basal insulin Fc | News

Second weekly insulin shows phase 2 promise for type 2 diabetes

A novel weekly insulin achieves similar glycemic control to insulin degludec at a higher fasting glucose target, report the investigators at the virtual ENDO 2021 meeting.

07-03-2020 | Physical activity | News

Fructose boost may alleviate type 1 diabetes exercise-induced hypoglycemia risk

Consuming a single shot of fructose prior to exercise is a feasible strategy to reduce the risk for exercise-induced hypoglycemia among men with type 1 diabetes treated with insulin degludec, suggest findings from a proof-of-concept study.

Related topics

Superior

Related